Drug intelligence / Profile preview

S-120083

Development stage: Phase 2
Lead developer: Shionogi
Modality: Small Molecules
Administration: Oral

Overview

S-120083 (also known as V120083) is an orally administered small molecule analgesic and anti-inflammatory agent developed by Shionogi and Purdue Pharma for the treatment of moderate to severe chronic pain, particularly due to osteoarthritis of the knee and other inflammatory pain conditions. The precise mechanism of action remains undefined. It has reached Phase 2 clinical trials in the United States and Japan for indications including chronic pain and knee osteoarthritis.

Beyond the preview

Go deeper on S-120083.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-120083.

Explore the full profile